Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review
- PMID: 30463072
- DOI: 10.1159/000494359
Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review
Abstract
Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial. A comprehensive review of the literature has been carried out. An electronic search of databases from PubMed, Scopus, Google Scholar was implemented. The search terms were: "BC," "bladder carcinoma," "bladder neoplasm," "human epidermal growth factor 2," "HER2," "HER-2," "c-erbB-2," "c-erbB2," "erbB-2," "erbB2," "neu," "marker," "biomarker," and "prognosis". Results of the review consented to (a) summarize the available data on HER2 a predictor of recurrence and/or progression free survival on univariate and multivariate analysis, (b) explore the related issues in assessing HER2 status on these tumor samples, since they may severely impair its predictive function, and (c) report the state-of-the art of HER2 as a putative therapeutic target in BC and especially non-muscle invasive BC. HER2 stands out for being a prognostic factor as well as a therapeutic target in various cancers. Data from the literature concerning its use in BC provide conflicting results, probably due to the inherent complexity of BC biology. Efforts should be made to establish a suitable tumor-specific scoring system, and to assess single drugs' efficacy in well-designed clinical trials.
Keywords: Bladder cancer; Human epidermal growth factor receptor 2; Non-muscle invasive bladder cancer; Prognosis; Therapeutic target.
© 2018 S. Karger AG, Basel.
Similar articles
-
HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.Int J Mol Sci. 2023 Feb 13;24(4):3720. doi: 10.3390/ijms24043720. Int J Mol Sci. 2023. PMID: 36835131 Free PMC article. Review.
-
Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance.Urologia. 2023 May;90(2):248-260. doi: 10.1177/03915603221150965. Epub 2023 Jan 20. Urologia. 2023. PMID: 36670543
-
Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.Ann Diagn Pathol. 2019 Apr;39:42-52. doi: 10.1016/j.anndiagpath.2019.01.002. Epub 2019 Jan 17. Ann Diagn Pathol. 2019. PMID: 30684846
-
A systematic review of dual targeting in HER2-positive breast cancer.Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Cancer Treat Rev. 2014. PMID: 24080156 Review.
-
Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy.Int Urol Nephrol. 2008;40(2):321-7. doi: 10.1007/s11255-007-9283-x. Int Urol Nephrol. 2008. PMID: 17899426
Cited by
-
RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).Front Oncol. 2024 Jan 10;13:1233196. doi: 10.3389/fonc.2023.1233196. eCollection 2023. Front Oncol. 2024. PMID: 38269021 Free PMC article.
-
Characterization of circSCL38A1 as a novel oncogene in bladder cancer via targeting ILF3/TGF-β2 signaling axis.Cell Death Dis. 2023 Jan 25;14(1):59. doi: 10.1038/s41419-023-05598-2. Cell Death Dis. 2023. PMID: 36697384 Free PMC article.
-
Prognostic significance of HER2 status evaluation using immunohistochemistry in patients with urothelial carcinoma of the bladder: A retrospective single‑center experience.Exp Ther Med. 2022 Oct 4;24(5):704. doi: 10.3892/etm.2022.11640. eCollection 2022 Nov. Exp Ther Med. 2022. PMID: 36324611 Free PMC article.
-
Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.Int J Mol Sci. 2022 Jul 16;23(14):7844. doi: 10.3390/ijms23147844. Int J Mol Sci. 2022. PMID: 35887192 Free PMC article. Review.
-
The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: A Meta-Analysis and a Bioinformatic Analysis.Front Oncol. 2021 Sep 1;11:653491. doi: 10.3389/fonc.2021.653491. eCollection 2021. Front Oncol. 2021. PMID: 34540657 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous